- Home
- ISPC vs VRAX Comparison
ISPC vs VRAX Comparison
Compare ISPC & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- VRAX
- Stock Information
- Founded
- ISPC 2009
- VRAX 2013
- Country
- ISPC United States
- VRAX United Kingdom
- Employees
- ISPC N/A
- VRAX N/A
- Industry
- ISPC Precision Instruments
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ISPC Health Care
- VRAX Health Care
- Exchange
- ISPC Nasdaq
- VRAX Nasdaq
- Market Cap
- ISPC 4.6M
- VRAX 4.4M
- IPO Year
- ISPC 2021
- VRAX 2022
- Fundamental
- Price
- ISPC $1.73
- VRAX $0.57
- Analyst Decision
- ISPC
- VRAX Strong Buy
- Analyst Count
- ISPC 0
- VRAX 1
- Target Price
- ISPC N/A
- VRAX $3.00
- AVG Volume (30 Days)
- ISPC 16.2M
- VRAX 1.4M
- Earning Date
- ISPC 11-06-2025
- VRAX 01-01-0001
- Dividend Yield
- ISPC N/A
- VRAX N/A
- EPS Growth
- ISPC N/A
- VRAX N/A
- EPS
- ISPC N/A
- VRAX N/A
- Revenue
- ISPC $5,908,088.00
- VRAX $6,331.00
- Revenue This Year
- ISPC $35.93
- VRAX $217,274.83
- Revenue Next Year
- ISPC N/A
- VRAX N/A
- P/E Ratio
- ISPC N/A
- VRAX N/A
- Revenue Growth
- ISPC N/A
- VRAX N/A
- 52 Week Low
- ISPC $0.64
- VRAX $0.52
- 52 Week High
- ISPC $8.30
- VRAX $3.62
- Technical
- Relative Strength Index (RSI)
- ISPC 62.83
- VRAX 32.48
- Support Level
- ISPC $1.05
- VRAX $0.54
- Resistance Level
- ISPC $3.18
- VRAX $0.59
- Average True Range (ATR)
- ISPC 0.35
- VRAX 0.05
- MACD
- ISPC 0.10
- VRAX 0.00
- Stochastic Oscillator
- ISPC 42.91
- VRAX 20.24
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).